Pharmacological treatment of cardiogenic shock - A state of the art review
- PMID: 35697151
- DOI: 10.1016/j.pharmthera.2022.108230
Pharmacological treatment of cardiogenic shock - A state of the art review
Abstract
Cardiogenic shock is a clinical syndrome of impaired tissue perfusion caused by primary cardiac dysfunction and inadequate cardiac output. It represents one of the most lethal clinical conditions in intensive care medicine with mortality >40%. Management of different clinical presentations of cardiogenic shock includes guidance of cardiac preload, afterload, heart rate and contractility by differential pharmacological modulation of volume, systemic and pulmonary vascular resistance and cardiac output besides reversing the triggering cause. Data from large registries and randomized controlled trials on optimal diagnostic guidance as well as choice of pharmacological agents has accrued significantly in recent years. This state-of-the-art review summarizes the basic concepts of cardiogenic shock, the diagnostic work-up and currently available evidence and guideline recommendations on pharmacological treatment of cardiogenic shock.
Keywords: Cardiogenic shock; Heart failure; Pharmacological treatment.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest No conflicts to disclose.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
